Filing of Form 10-Q for Second Quarter

RNS Number : 6259V
MaxCyte, Inc.
11 August 2022
 

 

 

 

 

MaxCyte announces filing of Form 10-Q for the quarterly period ended June 30, 2022

 

 

ROCKVILLE, MD, August 11, 2022  - MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), aleading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization,today announced that it has filed a Form 10-Q with the SEC for the quarterly period ended June 30, 2022.

 

A copy of the Form 10-Q is available to view on the SEC's website at www.sec.gov and has also been posted to the "SEC filings" page of the Company's website, https://investors.maxcyte.com/.

 

 

 

MaxCyte Contacts:

 

US IR Adviser  

Gilmartin Group  

David Deuchler, CFA 

+1 415-937-5400  

ir@maxcyte.com  

 

US Media Relations

Seismic

Valerie Enes

 

Nominated Adviser and Joint Corporate Broker  

Panmure Gordon  

Emma Earl / Freddy Crossley  

Corporate Broking  

Rupert Dearden  

 

+1 408-497-8568

 

 

 

+44 (0)20 7886 2500  

UK IR Adviser

Consilium Strategic Communications

Mary-Jane Elliott

Chris Welsh

 

 

+44 (0)203 709 5700

maxcyte@consilium-comms.com

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCURVNRURUWAAR
UK 100

Latest directors dealings